Literature DB >> 20382224

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Chen Yao1, Rabih El Khoury, Wen Wang, Tara A Byrd, Elizabeth A Pehek, Colin Thacker, Xiongwei Zhu, Mark A Smith, Amy L Wilson-Delfosse, Shu G Chen.   

Abstract

Mutations in LRRK2 are thus far the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease (PD) with prevalent mutations being found within the GTPase (R1441C/G) and kinase (G2019S) domains. Previous in vitro studies have revealed that R1441C and G2019S mutations are associated with increased kinase activity. To better understand LRRK2-linked PD pathogenesis in vivo, we have generated transgenic C. elegans overexpressing human LRRK2 wild type, R1441C and G2019S in dopaminergic (DA) neurons. Overexpression of these LRRK2 proteins causes age-dependent DA neurodegeneration, behavioral deficits, and locomotor dysfunction that are accompanied by a reduction of dopamine levels in vivo. In comparison, R1441C and G2019S mutants cause more severe phenotypes than the wild type protein. Interestingly, treatment with exogenous dopamine rescues the LRRK2-induced behavioral and locomotor phenotypes. In contrast, expression of the GTP binding defective mutant, K1347A, or knockout of the C. elegans LRRK2 homolog, LRK-1, prevents the LRRK2-induced neurodegeneration and behavioral abnormalities. Hence, our transgenic LRRK2 C. elegans models recapitulate key features of PD including progressive neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and reduction in dopamine levels. Furthermore, our findings provide strong support for the critical role of GTPase/kinase activity in LRRK2-linked pathologies. These invertebrate models will be useful for studying pathogenesis of PD and for development of potential therapeutics for the disease. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382224      PMCID: PMC2926296          DOI: 10.1016/j.nbd.2010.04.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

1.  C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway.

Authors:  E R Sawin; R Ranganathan; H R Horvitz
Journal:  Neuron       Date:  2000-06       Impact factor: 17.173

2.  Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans.

Authors:  Richard Nass; David H Hall; David M Miller; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

3.  LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.

Authors:  Shamol Saha; Maria D Guillily; Andrew Ferree; Joel Lanceta; Diane Chan; Joy Ghosh; Cindy H Hsu; Lilach Segal; Kesav Raghavan; Kunihiro Matsumoto; Naoki Hisamoto; Tomoki Kuwahara; Takeshi Iwatsubo; Landon Moore; Lee Goldstein; Mark Cookson; Benjamin Wolozin
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

4.  Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.

Authors:  Christian L Klein; Giorgio Rovelli; Wolfdieter Springer; Christoph Schall; Thomas Gasser; Philipp J Kahle
Journal:  J Neurochem       Date:  2009-08-27       Impact factor: 5.372

5.  Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.

Authors:  Saurabh Sen; Philip J Webber; Andrew B West
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 6.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

7.  Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth.

Authors:  Julia Sämann; Jan Hegermann; Erika von Gromoff; Stefan Eimer; Ralf Baumeister; Enrico Schmidt
Journal:  J Biol Chem       Date:  2009-02-27       Impact factor: 5.157

8.  R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.

Authors:  Youren Tong; Antonio Pisani; Giuseppina Martella; Maha Karouani; Hiroo Yamaguchi; Emmanuel N Pothos; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

Review 9.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

10.  An imaging system for standardized quantitative analysis of C. elegans behavior.

Authors:  Zhaoyang Feng; Christopher J Cronin; John H Wittig; Paul W Sternberg; William R Schafer
Journal:  BMC Bioinformatics       Date:  2004-08-26       Impact factor: 3.169

View more
  53 in total

Review 1.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  Perfluorooctane Sulfonate (PFOS) Produces Dopaminergic Neuropathology in Caenorhabditis elegans.

Authors:  Shreesh Raj Sammi; Rachel M Foguth; Claudia Sofía Nieves; Chloe De Perre; Peter Wipf; Cynthia T McMurray; Linda S Lee; Jason R Cannon
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

3.  LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.

Authors:  Dan Hu; Jian-Yi Niu; Jing Xiong; Shu-Ke Nie; Fei Zeng; Zhao-Hui Zhang
Journal:  Curr Med Sci       Date:  2018-12-07

Review 4.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

5.  Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in Caenorhabditis elegans.

Authors:  Latasha L Smith; Ian T Ryde; Jessica H Hartman; Riccardo F Romersi; Zachary Markovich; Joel N Meyer
Journal:  Neurotoxicology       Date:  2019-07-16       Impact factor: 4.294

Review 6.  Tied up: Does altering phosphoinositide-mediated membrane trafficking influence neurodegenerative disease phenotypes?

Authors:  Sravanthi S P Nadiminti; Madhushree Kamak; Sandhya P Koushika
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 7.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease.

Authors:  William M Johnson; Marcin Golczak; Kyonghwan Choe; Pierce L Curran; Olga Gorelenkova Miller; Chen Yao; Wenzhang Wang; Jiusheng Lin; Nicole M Milkovic; Ajit Ray; Vijayalakshmi Ravindranath; Xiongwei Zhu; Mark A Wilson; Amy L Wilson-Delfosse; Shu G Chen; John J Mieyal
Journal:  Biochemistry       Date:  2016-08-01       Impact factor: 3.162

Review 9.  Current Opinions and Consensus for Studying Tremor in Animal Models.

Authors:  Sheng-Han Kuo; Elan D Louis; Phyllis L Faust; Adrian Handforth; Su-Youne Chang; Billur Avlar; Eric J Lang; Ming-Kai Pan; Lauren N Miterko; Amanda M Brown; Roy V Sillitoe; Collin J Anderson; Stefan M Pulst; Martin J Gallagher; Kyle A Lyman; Dane M Chetkovich; Lorraine N Clark; Murni Tio; Eng-King Tan; Rodger J Elble
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

10.  Regulation of autophagy by LRRK2 in Caenorhabditis elegans.

Authors:  Shamol Saha; Liqun Liu-Yesucevitz; Benjamin Wolozin
Journal:  Neurodegener Dis       Date:  2013-10-31       Impact factor: 2.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.